Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation-Reference-Cited by-同舟云学术

Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation

Published:2012-08 Issue:2 Volume:77 Page:460-463
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Lee June Koo,Kim Tae Min,Koh Youngil,Lee Se-Hoon,Kim Dong-Wan,Jeon Yoon-Kyung,Chung Doo Hyun,Yang Seok-Chul,Kim Young Tae,Kim Young-Whan,Heo Dae Seog,Bang Yung-Jue

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference18 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

2. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

3. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

4. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med,2010

5. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4–ALK;Shaw;J Clin Oncol,2009

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing non-small cell lung cancer treatment: the power of combination immunotherapies;Frontiers in Immunology;2024-07-02

2. Targeted Therapy of Advanced Non-Small Cell Lung Cancer;The Korean Journal of Medicine;2024-04-01

3. Clinical Challenge of Two Competing Targetable Mutations in Non-Small-Cell Lung Cancer: A Case Report;Diagnostics;2023-10-02

4. Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-05

5. Synthesis and evaluation of sulfonamide derivatives targeting EGFR790M/L858R mutations and ALK rearrangement as anticancer agents;Bioorganic & Medicinal Chemistry;2023-05